FerroptoCure

Developing the world's first anticancer drug using ferroptosis

Tokyo, Japan · Founded 2022 · $6.5M raised

Headquarters
Tokyo
Employees
1–10
Founded
2022
Business Model
B2B
Total Funding
$6.5M
Last Round
$6.5M Series ASep 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

FerroptoCure Inc. is a Japanese clinical-stage biopharmaceutical company founded in May 2022, focused on developing the world's first anticancer drugs based on ferroptosis — a form of regulated cell death driven by iron-dependent lipid peroxidation. The company's novel mechanism targets the ferroptosis regulatory pathway to selectively kill cancer cells that are resistant to conventional therapies, addressing a significant unmet need in oncology. FerroptoCure has participated in global startup acceleration programs including the BioLabs LINK-BioBAY Masterclass and the CIC Global Startup Acceleration Program.

Summary

FerroptoCure is a Biotech company based in Tokyo, Japan, founded in 2022. It has raised $6.5M in total across 2 rounds, most recently a $6.5M Series A round in Sep 2025. Investors include Diamond Medino Capital and ANRI.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ASep 2025
$6.5M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

FerroptoCure on Indexed.vc
<a href="https://indexed.vc/companies/ferroptocure"><img src="https://indexed.vc/api/badge/company/ferroptocure" alt="FerroptoCure on Indexed.vc" width="260" height="76" /></a>